<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012025</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N0032</org_study_id>
    <secondary_id>CDR0000068473</secondary_id>
    <nct_id>NCT00012025</nct_id>
  </id_info>
  <brief_title>ICI 182780 in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial Of Fulvestrant (Faslodex) In Women With Metastatic Breast Cancer And Failure on Aromatase Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using&#xD;
      ICI 182780 may fight breast cancer by blocking the activity of estrogen in the tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of ICI 182780 in treating patients who&#xD;
      have metastatic breast cancer that has not responded to previous hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete and partial objective response rate and duration of response in&#xD;
           women with metastatic breast cancer who have failed aromatase inhibitor therapy treated&#xD;
           with fulvestrant.&#xD;
&#xD;
        -  Determine the time to disease progression and overall survival of women treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these women.&#xD;
&#xD;
      OUTLINE: Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 5 years or until disease progression. After disease&#xD;
      progression, patients are followed every 3 months for 2 years and then every 6 months for 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to disease progression</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <arm_group_label>fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Progressive local-regional or metastatic disease&#xD;
&#xD;
               -  Unconfirmed new or progressive multiple pulmonary nodules or unequivocal&#xD;
                  radiographic evidence of multiple bone metastases allowed&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  At least 20 mm by CT scan or MRI OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable disease includes the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusions&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  Disease progression after prior third-generation aromatase inhibitor (e.g.,&#xD;
             anastrozole, exemestane, letrozole, or vorozole)&#xD;
&#xD;
               -  Failed no more than 1 prior additive hormonal therapy (e.g., aromatase inhibitor&#xD;
                  with or without tamoxifen)&#xD;
&#xD;
                    -  Disease recurrence identified no more than 12 months since the last prior&#xD;
                       adjuvant tamoxifen treatment&#xD;
&#xD;
                    -  Oophorectomy, ovarian radiotherapy, and luteinizing hormone-releasing&#xD;
                       hormone (LH-RH) analogs not considered hormonal therapy regimens&#xD;
&#xD;
          -  No brain or leptomeningeal metastases&#xD;
&#xD;
          -  No hepatic metastases involving more than one-third of the liver&#xD;
&#xD;
          -  No symptomatic pulmonary lymphangitic disease&#xD;
&#xD;
          -  Evidence of hormone sensitivity as defined by:&#xD;
&#xD;
               -  Relapse after at least 12 months of adjuvant hormonal treatment&#xD;
&#xD;
               -  Tumor remission or stabilization before progression for at least 6 months after&#xD;
                  prior hormonal therapy for advanced disease&#xD;
&#xD;
          -  Postmenopausal as defined by one of the following:&#xD;
&#xD;
               -  At least 12 months since last menstrual period&#xD;
&#xD;
               -  4-11 months since last menstrual period and follicle-stimulating hormone (FSH) in&#xD;
                  the postmenopausal range&#xD;
&#xD;
               -  Prior castration and castrate FSH levels within the postmenopausal range&#xD;
&#xD;
               -  Hysterectomy without oophorectomy (FSH in postmenopausal range if age 60 and&#xD;
                  under)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen-receptor and/or progesterone-receptor positive&#xD;
&#xD;
                    -  At least 10 fmol/mg cytosol protein OR&#xD;
&#xD;
                    -  Positive by immunohistochemistry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No history of bleeding diathesis&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin no greater than 0.8 mg/dL above upper limit of normal (ULN)&#xD;
&#xD;
          -  INR no greater than 1.6&#xD;
&#xD;
          -  No hepatitis B or C&#xD;
&#xD;
          -  No severe hepatic impairment&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Calcium no greater than 10% above ULN&#xD;
&#xD;
          -  Creatinine no greater than 1 mg/dL above ULN&#xD;
&#xD;
          -  No severe renal impairment&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable or uncompensated cardiac condition&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No unstable or uncompensated respiratory condition&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS&#xD;
&#xD;
          -  No other severe condition or systemic disease that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior trastuzumab (Herceptin) allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior estrogen replacement therapy&#xD;
&#xD;
          -  More than 3 months since prior LH-RH analogs&#xD;
&#xD;
          -  No other prior additive hormonal therapy except third-generation aromatase inhibitors&#xD;
             or tamoxifen&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent radiotherapy for control of bone pain or other reasons due to established&#xD;
             bone lesions allowed if radiotherapy field is no more than 30% of bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drug for breast cancer&#xD;
&#xD;
          -  No concurrent long-term warfarin&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed if dose stable&#xD;
&#xD;
          -  Concurrent long-term antiplatelet therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James N. Ingle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MBCCOP - Gulf Coast</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mayo Clinic Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One Health System</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Merit Care Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Geisinger Clinic and Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212-4772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA; North Central Cancer Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006 Mar 1;24(7):1052-6.</citation>
    <PMID>16505423</PMID>
  </results_reference>
  <results_reference>
    <citation>Ingle JN, Rowland KM, Suman VJ, et al.: Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. [Abstract] Breast Cancer Res Treat 88 (1): A-409, 2004.</citation>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

